London-based startup Epoch Biodesign has raised €17 million in Series A funding to advance its innovative enzyme technology for recycling plastic waste.
Information on the Target
Epoch Biodesign, a London-based startup, has developed innovative technology utilizing enzymes to efficiently and cost-effectively recycle plastic waste. The company has successfully raised €17 million (approximately KRW 20 billion) in a Series A funding round, led by Extantia Capital, with participation from notable investors such as Inditex and Lowercarbon Capital. Additionally, Epoch has secured a grant of €929,000 (around KRW 1.1 billion) from the UK government.
Founded in 2019, Epoch Biodesign focuses on transforming waste plastics into valuable chemicals using artificial intelligence and synthetic biology. The funding will primarily be used for establishing its first factory, expanding plastic-decomposing enzyme production, and servicing clients in the fashion, automotive, and chemical industries. The company plans to process tens of thousands of tons of plastic waste by 2028. CEO Jacob Nathan expressed a vision of converting plastic waste into a resource, enabling competitive pricing for recycled plastics.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The plastic recycling industry in the UK is rapidly evolving in response to increasing environmental concerns and regulatory pressures. With government initiatives targeting a circular economy, there is a strong impetus for innov
Similar Deals
Extantia Capital
invested in
Epoch Biodesign
in 2025
in a Series A deal
Disclosed details
Transaction Size: $17M
Enterprise Value: $32M
Equity Value: $20M